`
`Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
`
`U.S. Food and Drug Administration
`Protecting and Promoting Your Health
`
`Orange Book: Approved Drug Products
`with Therapeutic Equivalence Evaluations
`
`
`f SHARE (HTTPS:/)WWW.FACEBOOK.COM/SHARER/SHARER.PHP?
`U=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/RESULTS PRODUCT.CFM?APPL_TYPE=N&APPL_NO=201023
`
`WV TWEET(HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE
`EVALUATIONS&URL=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/RESULTS PRODUCT.CFM?APPL_TYPE=N&APPL_NO=201023
`
`+ M
`
`@ EMAIL (MAILTO:?SUBJECT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE
`EVALUATIONS&BODY=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/RESULTS_PRODUCT.CFM?APPL_TYPE=N&APPL_NO=201023
`
`Home(default.cfm?resetfields=1) | Back to Search Results
`
`Product Details for NDA 201023
`
`JEVTANAKIT (CABAZITAXEL)
`60MG/1.5ML (40MG/ML)
`
`Marketing Status: Prescription
`
`Active Ingredient: CABAZITAXEL
`Proprietary Name: JEVTANAKIT
`Dosage Form; Route of Administration: SOLUTION; IV (INFUSION)
`Strength: GOMG/1.5ML (40MG/ML)
`Reference Listed Drug: Yes
`TE Code:
`Application Number: N201023
`Product Number: 001
`Approval Date: Jun 17, 2010
`Applicant Holder Full Name: SANOFI! AVENTIS US INC
`Marketing Status: Prescription
`Patent and Exclusivity Information
`(patent_info.cfm?
`
`
`http:/Awww.accessdata.fda.gov/scripts/cder/ob/results_product.cim?Appl_Type=N&Appl_No=201023
`
`1
`
`JANSSEN EXHIBIT 2108
`Amerigen v. Janssen IPR2016-00286
`
`JANSSEN EXHIBIT 2108
`Amerigen v. Janssen IPR2016-00286
`
`